We characterized the uptake of carnitine in brush-border membrane (BBM) and basolateral membrane (BLM) vesicles, isolated from mouse kidney and intestine. In kidney, carnitine uptake was Na -dependent, showed a definite overshoot and was saturable for both membranes, but for intestine, it was Na -dependent only in BLM. The uptake was temperaturedependent in BLM of both kidney and intestine. The BBM transporter in kidney had a high affinity for carnitine : apparent K m = 18.7 WM; V max = 7.85 pmol/mg protein/s. In kidney BLM, similar characteristics were obtained: apparent K m = 11.5 WM and V max = 3.76 pmol/mg protein/s. The carnitine uptake by both membranes was not affected within the physiological pH 6.5^8.5. Tetraethylammonium, verapamil, valproate and pyrilamine significantly inhibited the carnitine uptake by BBM but not by BLM. By Western blot analysis, the OCTN2 (a Na -dependent high-affinity carnitine transporter) was localized in the kidney BBM, and not in BLM. Strong OCTN2 expression was observed in kidney and skeletal muscle, with no expression in intestine in accordance with our functional study. We conclude that different polarized carnitine transporters exist in kidney BBM and BLM. L-Carnitine uptake by mouse renal BBM vesicles involves a carrier-mediated system that is Na -dependent and is inhibited significantly by specific drugs. The BBM transporter is likely to be OCTN2 as indicated by a strong reactivity with the anti-OCTN2 polyclonal antibody. ß
Introduction
Carnitine, L-hydroxy Q-N-trimethylammonium butyrate, is an essential cofactor for the transfer of long-chain fatty acids from the cytosol into mitochondria for subsequent L-oxidation. Another well established function of carnitine is the maintenance of the cellular coenzyme-A pool [1] . In humans, Lcarnitine is obtained from dietary sources, primarily meat and dairy products, and produced endogenously from the amino acids lysine and methionine, with both sources contributing to plasma and tissue levels.
The major site of L-carnitine absorption is the small intestine but the mechanism of intestinal uptake of L-carnitine is unclear. Earlier studies using intact intestinal tissue preparations suggested that intestinal L-carnitine uptake occurred by a carrier-mediated process [2] , but in a subsequent study using rat intestinal brush-border membrane (BBM) vesicles, it was concluded that the uptake process is a passive di¡usion [3] . Thus, the mechanism of the L-carnitine uptake process remains controversial. More recently, McCloud et al. [4] showed that the L-carnitine uptake by intestinal epithelial cells (Caco-2) involves a carrier-mediated system (K m of 45 WM) that is temperature-, Na -and energydependent.
Dietary intake and carnitine biosynthesis are responsible to maintain the carnitine body stores in mammals [5] . Carnitine is eliminated as free carnitine or acylcarnitine almost exclusively by the kidneys, where it is ¢ltered and reabsorbed by s 95% in the proximal tubule [1] . The kidney has in fact a crucial role in homeostatic regulation of carnitine concentration in body £uids. The carnitine reabsorption appears to be regulated such that normal plasma carnitine concentration (30^90 WM) is maintained without signi¢cant loss of carnitine in the urine [6] . When carnitine reabsorption is impaired, e.g. in patients with primary carnitine de¢ciency [7] , the plasma and tissue carnitine concentrations decrease and clinical symptoms of carnitine de¢ciency can develop, underlining the importance of the renal carnitine transport system. Solute reabsorption by the kidney is a multistep process implying translocation of the substrate across the luminal and removal to the circulation by passage across the anti-luminal membrane (basolateral membrane, BLM) [8] . For carnitine, the renal transport system has been characterized in rat kidney BBM vesicles [8, 9] . These studies revealed Na -dependent, saturable transport of L-carnitine, with K m of 55 WM [8] and two transport systems with K m values of 17 WM and 15 mM [9] . The transport could be inhibited by structural analogues such as D-carnitine, butyrobetaine, L-acetyl-carnitine but not by glycinebetaine. No study of carnitine transport in mouse apical or BLM vesicles has been reported.
De¢ciency states occur when dietary sources are inadequate (such as in vegetarian diets), gastrointestinal absorption is decreased, renal losses are excessive, or endogenous production is inadequate secondary to an enzyme de¢ciency. Primary systemic carnitine de¢ciency (SCD; OMIM 212140) in human patients causes severe pathological symptoms such as cardiomyopathy, muscle weakness, fasting hypoglycemia and sudden death [10, 11] . It is also characterized by excessive losses of intestinal and urinary carnitine [12] . SCD is transmitted in an autosomal recessive manner. It is caused by mutations in the OCTN2 gene which encodes a carnitine and organic cation transporter (OCT) cloned recently [13, 14] . The OCTN2 protein has 557 amino acids with 12 putative transmembrane domains. Until now, three transporters of carnitine have been identi¢ed, and called OCTN1, OCTN2 and OCTN3. They belong to the OCT family and have di¡erent characteristics, namely a¤nity and capacity for carnitine transport, energization of transport, and sensitivity to inhibitors. These transporters are expressed in several tissues, but the precise intracellular localization is unknown.
A mouse model known as jvs or`juvenile visceral steatosis' shows the same characteristics as the human SCD [15, 16] . The homozygous jvs mutants show a microvesicular fatty in¢ltration of the viscera, and a signi¢cant cardiomyopathy. These mice have low levels of carnitine in the serum, the liver and the skeletal and cardiac muscles. De¢ciency of carnitine transport has been demonstrated in the renal tubules, ¢broblasts and the hepatocytes (absence of the higha¤nity transporter, [17] ). Recently, it has been con¢rmed that the gene for the mouse carnitine transporter OCTN2 (located on chromosome 11) is mutated in the jvs strain. In this mutation, leucine 352 is changed to arginine in the sixth transmembrane domain of OCTN2 [18] .
A study of the physiology of L-carnitine transport in mice is important to understand the nature of human SCD and its mouse counterpart in the jvs model and to con¢rm the apical and/or BLM localization of OCTN2 in both kidney and small intestine. Our hypothesis is that di¡erent polarized carnitine transporters may exist in BBM and BLM. The rationale is based largely on analogy with other transport systems, such as renal K-ketoglutarate transporter [19] and lysine transporter implicated in lysinuric protein intolerance [20] . The properties of the two steps in carnitine absorption, transport across the renal and intestinal BBM and BLM, were evaluated by measuring the uptake of labeled substrate using puri¢ed membrane vesicles. Our results show that L-carnitine uptake by mouse renal BBM vesicles involves a Na -dependent carrier that is likely to be OCTN2. 
Materials and methods

Materials
Membrane vesicle preparation
BBM vesicles were isolated from the renal cortex and the proximal half of the small intestine of mice (strain C57-BL/6J), by the Mg 2 precipitation method described by Hauser et al. [21] . Renal cortex and intestine were immediately removed and rinsed with ice-cold 0.9% NaCl solution. BBM from renal cortices and intestinal mucosal scrapings were prepared as previously described [22] . BLM vesicles from renal cortices and intestinal mucosal scrapings were prepared by a Percoll density gradient centrifugation method as described by Edwards et al. [19] .
Biochemical assays
The protein determination was done by the method of Lowry et al. [23] using serum albumin as a standard. The degree of purity of membranes was assessed by measuring the enrichment of marker enzymes for the BBM, alkaline phosphatase [24] , and for the BLM, Na ,K -ATPase [25] . For the BBM, the relative enrichment of alkaline phosphatase over the original homogenate was 7.5 and 8 for intestine and kidney, respectively. For the BLM, the enrichment factor of Na ,K -ATPase was 8 for intestine, and 8.5 for kidney. These values compare closely to those obtained in rabbits [26] and are generally considered as satisfactory.
Uptake studies
Uptake of [
3 H]carnitine was done manually with manifold using cellulose nitrate ¢lters, 0.65 Wm pore size from Sartorius, Go « ttingen, Germany, or measured by a rapid ¢ltration method using the FSRFA (fast sampling rapid ¢ltration apparatus) as described by Malo and Berteloot [27] . BBM and BLM vesicles were usually resuspended in a ¢nal concentration of 15^20 mg of protein/ml in the ¢nal resuspension bu¡er (50 mM Tris^HEPES (N-2-hydroxyethylpiperazine-NP-2-ethanesulfonic acid), 0.1 mM MgSO 4 , 250 mM KCl, 125 mM mannitol, pH 7.5), and 20 Wl/0.5 ml incubation medium (¢nal concentrations: 50 mM Tris^HEPES, 0.1 mM MgSO 4 , 100 mM KCl, 150 mM NaCl, 125 mM, mannitol, pH 7.5) was used. The sodium-dependent uptake was determined by subtracting the sodium-independent (KCl only, 250 mM) uptake from the sodium-dependent (KCl 100 mM+NaCl 150 mM) uptake. (A) Manual uptake: L- [ 3 H]carnitine at 50 WM was added to the incubation medium and the reaction started by addition of membrane vesicles. After di¡erent incubation times, the uptake was stopped by adding 2 ml of ice-cold stop solution (cold resuspension bu¡er); the ¢lters were washed three times with 2 ml ice-cold stop solution before radioactivity counting. (B) Uptake with FSRFA: this apparatus allows for sampling of up to 18 aliquots from the same incubation mixture and fully automates the sequence of vesicle injection and mixing with the incubation medium, samplings, washings, and ¢ltrations. Carnitine uptake as a function of time was determined using nine aliquots of 50 Wl each at di¡erent time intervals and processed as described in [27] . For both approaches, corrections were made for [ 3 H]carnitine bound to the ¢lters in the absence of vesicles which was always 6 0.1% of added counts; the functional integrity of BBM vesicles was veri¢ed by testing Dglucose uptake by renal and intestinal preparations (v i = 2.63 þ 0.3 pmol/mg protein/s for kidney, and v i = 2.15 þ 0.24 pmol/mg protein/s for intestine).
Assays with xenobiotic inhibitors
Membrane vesicles were prepared as described above. The incubation medium contained (¢nal con-centrations) 50 WM L- [ 3 H]carnitine (1 WCi per assay), 50 mM Tris^HEPES, 0.1 mM MgSO 4 , 100 mM KCl, 150 mM NaCl, 125 mM mannitol, pH 7.5, and 500 WM of the xenobiotic. Transport was started by adding 6 Wl of membrane suspension to 48 Wl of preheated incubation medium (37³C). The reaction was stopped after 8 s for BBM, and 4 s for BLM.
Membrane localization and tissue distribution study by Western blot analysis
Rabbit polyclonal antibodies were raised against a synthesized polypeptide of mouse OCTN2 through Research Genetics, Inc. (Huntsville AL, USA). The amino acid sequence used was QWQIQSQTRMQKDGEESPT corresponding to amino acids 532^550 of OCTN2. Mouse tissues were isolated and homogenized in 4 ml bu¡er containing 10 mM Tris^HCl and 50 mM mannitol (pH 7.4) using a polytron homogenizer. The solution was then dispersed ultrasonically. After addition of sample bu¡er 2U (4% sodium dodecyl phosphate (SDS), 20% glycerol, 200 mM dithiothreitol, 120 mM Tris, pH 6.8, and 0.002% bromophenol blue) to the tissue homogenate or to the membrane vesicles, the solution was mixed, the proteins were denatured in a boiling water bath for 5 min and used for Western blot analysis. The sample was separated by 7.5% SDS^polyacrylamide gel electrophoresis (SDS^PAGE) and proteins were transferred to polyvinylidene di£uoride membrane Immobilon (Millipore, Bedford, MA, USA) which was incubated in phosphate-bu¡ered saline (PBS) bu¡er (150 mM NaCl, 2.5 mM KCl, 5 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) containing 0.02% sodium azide and 12% skim milk. The membrane was incubated with polyclonal anti-peptide antibody (in PBS bu¡er containing 0.02% sodium azide and 1% bovine serum albumin) overnight, rinsed with the above bu¡-er without skim milk (but with 0.1% Tween 20), and incubated with secondary antibody (goat anti-rabbit IgG, horseradish peroxidase-linked whole antibody, Sigma, St. Louis, MO, USA). The membrane was washed as before and the proteins were detected by a chemiluminescence detection method using BM Chemiluminescence ELISA Substrate (POD) (Boehringer Mannheim, Laval, QC, Canada). The molecular weights were estimated by using prestained SDS^PAGE standards, broad range (BioRad Laboratories, Hercules, CA, USA).
Results
Stability of BBM and BLM vesicles
Since there have been reports on the instability of BBM in rabbits and rats [28] and since uptake experiments usually last for a few hours, we have ¢rst veri¢ed the stability of both mice BBM and BLM vesicles by measuring the initial rates of 50 WM Lcarnitine uptake after 10, 20, 40, 60 and 120 min (not shown) after thawing membrane vesicles from liquid nitrogen. In BBM, the initial rates of L-carnitine transport remained constant for 10 min, and then decreased abruptly to 60%. In BLM, the L-carnitine transport remained constant for 60 min, and decreased later on. All experiments reported in the following studies have been performed on both BBM and BLM within 10 min after thawing from liquid nitrogen, as during this period, both these preparations would remain stable. Fig. 1 . Relationship between initial rates of L-carnitine uptake by renal BBM (squares) and renal BLM (circles) and membrane protein concentrations. Vesicles were prepared as described under Section 2. The initial rates of L-carnitine uptake have been determined at 37³C over the linear portion of the uptake time (8 s for BBM and 3 s for BLM, see Fig. 2 ). When not shown, the error bars were smaller than the symbols used. Linear regression analysis over the data points gave a correlation coe¤cient of 0.987 and 0.974 for BBM and BLM, respectively (n = 2 determinations).
Linearity of L-carnitine uptake with protein concentrations
Renal BBM and BLM vesicles were resuspended at di¡erent protein concentrations ranging from 4 to 30 mg per ml. As demonstrated in Fig. 1 , the initial rates of transport determined at a 50 WM L-carnitine concentration were linear over this range of protein concentrations for both membranes. All the following experiments have been performed using concentrations of 15^20 mg of BBM or BLM proteins per ml of resuspension medium. (Fig. 2B) . These results indicated a Na -coupled carnitine transport in both membranes.
Temperature dependency of L-carnitine uptake by renal BLM
Carnitine uptake by renal BLM was very fast. In order to slow down the carnitine uptake, we deter- mined the initial rate of carnitine uptake at two di¡erent temperatures, 37³C and 25³C. At 25³C, the uptake was linear with time for 6 s (inset, v i = 0.21 þ 0.01 pmol/mg protein/s), showed an overshoot at 8 s (Fig. 3) and was much higher in the presence of a Na gradient (data not shown). Further experiments with renal BLM were performed at 25³C.
Kinetics of carnitine uptake by renal BBM and BLM vesicles
To determine kinetic parameters for Na -dependent carnitine uptake by renal BBM and BLM vesicles in mice, the initial rates of L-carnitine uptake were determined at di¡erent concentrations of unlabeled substrate (Fig. 4A,B) . The kinetic parameters calculated by the Michaelis^Menten equation for one transport site were determined as described in [27] , and were similar for the two membrane preparations. The intravesicular pH was kept at pH 7.5 and the uptake medium pH was varied from 6.5 to 8.5. Initial rates of uptake were measured in the presence of a Na gradient as described in Fig. 4 . Results are the mean þ S.D. from three di¡erent experiments. (B) E¡ect of xenobiotics on L-carnitine transport by renal BBM and BLM. Membrane vesicles were incubated with 500 WM of each xenobiotic. Initial rates of carnitine uptake were measured in the presence of a Na gradient as described in Fig. 4 . Results are the mean þ S.D. from three di¡erent experiments. The apparent a¤nity (K m ) of the BBM transporter for carnitine was 18.7 þ 2.4 WM with a maximum transport rate (V max ) of 7.85 þ 0.82 pmol/mg protein/s. Likewise, in BLM vesicles, the apparent K m was 11.5 þ 1.8 WM and V max was 3.76 þ 0.66 pmol/mg protein/s.
E¡ect of extravesicular pH
The e¡ect of varying the extravesicular pH on renal BBM and BLM carnitine uptake was examined while keeping the intravesicular pH at 7.5. We found that changing extravesicular pH from 7.5 to either 6.5 or 8.5 did not signi¢cantly a¡ect BBM and BLM carnitine uptake (Fig. 5A) .
E¡ect of xenobiotics on L-carnitine transport by membrane vesicles
The ability of some drugs interacting with OCTN2 [29, 30] to inhibit carnitine transport by mouse renal BBM and BLM was investigated (Fig. 5B) . While TEA, valproate, verapamil and pyrilamine had no e¡ect on the initial rate of carnitine uptake by renal BLM, these compounds inhibited signi¢cantly (inhibition between 27% and 54%) carnitine transport by renal BBM.
Renal membrane localization and tissue distribution of OCTN2
The mouse renal membrane localization of OCTN2 was investigated by Western blot (in view of the importance of kidney in the secretion and reabsorption of drugs, xenobiotics, and organic endogenous compounds, and because OCTN2 is better expressed in kidney). The BBM and BLM were isolated from mouse renal cortex and probed with the polyclonal antibodies. The mouse OCTN2-speci¢c antibody labeled protein at the BBM with an apparent molecular mass of 70^80 kDa (Fig. 6A) . BLM showed no immunoreactivity for the antibody (Fig.  6A) .
The tissue distribution of OCTN2 was also determined by Western blot analyses (Fig. 6C) . The polyclonal antibodies recognized proteins of 70 and/or 80 kDa in immunoblot of homogenate proteins from various tissues. Expression pro¢le of OCTN2 protein Anti-peptide antibody speci¢c to OCTN2 was used. Renal or intestinal BBM and BLM from mouse (isolated as described under Section 2) (30 Wg/lane) and tissue homogenates prepared from mouse kidney, liver, heart, lung, brain, skeletal muscle, testis and intestine (30 Wg protein each) were separated on SDS^polyacrylamide gels (7.5%). To develop the Western blot, a peroxidase-coupled secondary antibody was used, and the reaction was visualized by chemiluminescence. Molecular weights (kDa) are shown on the left side.
was broad (expression in kidney, liver, heart and skeletal muscle, but not in brain, lung, intestine and testis), and strong in skeletal muscle.
Carnitine uptake by intestinal BBM and BLM vesicles
Similar studies as described for kidney were done for intestine. The purity, stability and functional integrity of intestinal membrane vesicles were comparable to those found in kidney (data not shown). The time courses of L-carnitine uptake and the in£uence of Na and temperature (37³C and 25³C) on carnitine transport by intestinal BBM and BLM were analyzed. In the presence of Na , carnitine uptake was di¡erent in the two membranes (Fig. 7) . In intestinal BBM vesicles (¢lled squares), carnitine accumulation showed very low values (Fig. 7) while in BLM vesicles (¢lled lozenges), carnitine uptake was linear up to 4 s in the presence of a Na gradient (Fig. 7) . In the absence of Na , there is no carnitine uptake in both membranes (not shown). The temperature e¡ect showed that at 25³C (Fig. 7, open lozenges) , the uptake was linear with time for 6 s. Moreover, the carnitine uptake by intestinal BLM was pH-independent since there were no signi¢cant di¡erences in uptake values when extravesicular pH was varied between 6.5 and 8.5 (Fig. 8) . Elsewhere, intestinal membrane localization studied by Western blot showed an absence of immunoreactivity between OCTN2 antibodies and both BBM and BLM (Fig.  6B ).
Discussion
We examined, for the ¢rst time in mice, the characteristics of carnitine uptake into BBM and BLM vesicles from renal cortices and intestinal mucosal scrapings. The use of isolated membrane vesicles avoided the interference of carnitine metabolism or carnitine uptake by other cellular compartments. We investigated, moreover, the localization at the luminal or basolateral plasma membrane of a recently cloned carnitine transporter, OCTN2, to understand its function in kidney and intestine.
Characterization of L-carnitine transport in the mouse kidney
In the mouse kidney, we found that there is a Na -dependent carnitine uptake across both BBM and BLM membranes with similar kinetic properties. These parameters were close to those found in rat BBM by Rebouche and Mack [8] and to the carnitine transport high-a¤nity system found in rat BBM by Stieger et al. [9] . In our studies the alteration of extravesicular pH between 6.5 and 8.5 had a minimal e¡ect on carnitine uptake by both BBM and BLM vesicles in mouse kidney. The examination of the extravesicular e¡ect of pH on BBM carnitine uptake is physiologically relevant because the in vivo pH of the proximal tubular £uid (equivalent to the extravesicular pH in the mostly right-side-out BBM vesicles) decreases along the proximal tubule, from 7.4 in the early proximal convoluted tubule to about 6.5 in the late proximal straight tubule [8] .
Although the qualitative aspects of carnitine transport were similar in the two membrane preparations from kidney, there were some di¡erences in the time courses of carnitine uptake. First, under Na gradient conditions and at 37³C, the period of linearity was shorter (4 s) in BLM vesicles than in BBM vesicles (10 s) which may be explained by a faster dissipation of the Na gradient. Second, the initial rate of carnitine uptake was more than two times higher in BBM than in BLM vesicles ( Fig. 2A,B ) which may re£ect a higher concentration of carrier molecules within the apical membrane. The substrate speci¢city of the transporter (s) was also di¡erent in the two kidney vesicle preparations. The organic cations TEA (nicotinic, cholinergic antagonist), verapa- mil (anti-angina, anti-arrhythmic), pyrilamine (antihistaminic), and the organic anion valproate (anticonvulsant, anti-epileptic) inhibited signi¢cantly carnitine uptake by BBM but not by BLM. This di¡er-ential e¡ect of various xenobiotics on carnitine uptake by renal membrane vesicles indicates clearly that there are di¡erent carnitine transporters in BBM and BLM from kidney. The lack of pH e¡ect on carnitine transport by renal membrane vesicles suggests that the transport mechanism is not a cotransport of carnitine/H in both mouse kidney BBM and BLM. This characteristic excludes an involvement of OCTN1 since this low-a¤nity transporter is pH-dependent in human [31] and rat [32] (although rOCTN1 does not mediate carnitine transport to any signi¢cant level) while pH dependency for mouse OCTN1 has not been previously tested [33] . The Na dependency of carnitine transport in renal BBM and BLM vesicles excludes the implication of the very recently cloned mouse Na -independent OCTN3 [33] .
Ohashi et al. [30] have tested the e¡ect of various xenobiotics on kidney cells (HEK, human epithelial kidney) transfected with the carnitine transporter hOCTN2 and found a signi¢cant inhibition by TEA, valproate, verapamil and pyrilamine. These data suggested that carnitine transport in mouse renal BBM implicates OCTN2, a physiologically important Na -dependent high-a¤nity carnitine transporter in humans [13, 14, 30] , rats [34, 35] and mice [18, 33] , because OCTN2 has the unique feature of being the only carnitine Na -dependent high-a¤nity transporter within the OCT superfamily. OCTN2 transports carnitine in a Na -dependent manner, but transports organic cations such as TEA, a prototypical organic cation, in a Na -independent manner, conferring one unique characteristic among the Na -coupled organic solute transporters cloned so far [13, 14] . In renal BLM, carnitine uptake was also a Na -dependent process but may involve a di¡erent carrier insensitive to any of the xenobiotics tested. In the presence of high levels of L-carnitine in the blood, the BLM transporter may have a regulatory role by preventing excessive accumulation of Lcarnitine in the renal tubular cells [8] . Also, if this transporter is multispeci¢c, it may be involved in the ¢rst step of elimination of drugs and xenobiotics in the urine.
Our hypothesis of polarized carnitine transporters in mouse kidney tubules was con¢rmed by Western blot analysis, which showed that OCTN2 is localized in BBM but not in BLM. Western blot indicated the proteins recognized by the antibody have molecular weights slightly over 70^80 kDa (Fig. 6 ) but close to the estimated size of OCTN2 deduced from the amino acid sequence (62 776 Da). This is probably referable to post-translational modi¢cation (such as phosphorylation or glycosylation). The strong expression of OCTN2 in kidney BBM supported its contribution to the reabsorption of carnitine from urine after glomerular ¢ltration to maintain carnitine content in body. Very recently, Tamai et al. [36] showed that OCTN2 is localized on the apical membrane of renal tubular epithelial cells in both mice and rats [36] . Valproate, a therapeutic molecule for epilepsy, induced carnitine de¢ciency, and it was suggested that the de¢ciency is related to a transporter-mediated interaction between carnitine and the drug molecule [37, 38] . Ohashi et al. [30] proposed that the competitive inhibition of hOCTN2-mediated carnitine transport by valproate may be one of the mechanisms of drug-induced carnitine de¢ciency. Since we found that valproate inhibited carnitine uptake by renal BBM and not by BLM, we suggest that this drug interacts with carnitine reabsorption by the OCTN2 transporter at the BBM level in kidney. The data do not exclude the possibility that the drug-induced carnitine de¢ciency during long-term treatment may be caused by inhibition of OCTN2-mediated carnitine transport in other tissues such as heart, skeletal muscle and liver, where OCTN2 is also strongly expressed. This correlates with the importance of carnitine function since more than 80% of carnitine is stored in muscle [39] . Heart and skeletal muscle are the two tissues which largely depend on carnitine to produce energy by long-chain fatty acid L-oxidation. More recently, Berardi et al. [40] have suggested the presence of the OCTN2 protein in the skeletal muscle by determining the properties of carnitine transport in plasma membrane vesicles from rat muscle. Only one previous study suggested that OCTN2 protein was present in the liver [17] , based on similar kinetic parameters (K m and V max ) found in cDNA OCTN2 transfected hepatocyte culture cells and membrane vesicles isolated from hepatocytes. Our tissue distribution is very close to that obtained recently by Tamai et al. [33] on Western blot by using antibodies raised against the divergent COOH-terminal portions of the OCTN2 protein. So, two di¡erent speci¢c anti-OCTN2 antibodies lead to the same results, although Tamai et al. [33] did not use skeletal muscle and intestine.
Characterization of L-carnitine transport in the mouse intestine
In the mouse intestine, we found that carnitine uptake by BBM was very low and Na -independent, while that by BLM was relatively high, temperatureand Na -dependent, but pH-independent (Fig. 7) . This indicates that carnitine transport systems are also di¡erent between BBM and BLM in the mouse intestine. All these results obtained with membrane vesicles correlate with McCloud's study [4] using Caco-2 cells as an intestinal model. A Western blot conducted in these membranes showed no immunoreactivity between polyclonal antibodies against OCTN2 with intestine (homogenate fraction) (Fig.  6C) and BBM or BLM fractions (Fig. 6B) , as in brain and lungs. So, Na -dependent carnitine transport in intestinal mouse BLM may be accomplished via a transporter other than OCTN2. This is supported by our ¢nding that carnitine uptake by intestinal BLM is pH-independent (Fig. 8) while a known characteristic of mouse OCTN2 is to mediate carnitine transport in a pH-dependent manner [33] . In rat intestine, a carnitine transporter called CT1 (carnitine transporter type 1) was cloned earlier [35] but it corresponds to OCTN2 which is not expressed in mouse small intestine. Our results also suggest that there are di¡erent carnitine transporters in BBM and BLM from intestine based on the di¡erent carnitine uptake characteristics observed in these membranes (Fig. 7) .
In summary, the present study shows the presence of di¡erent carrier-mediated systems for L-carnitine at the level of mouse renal and intestinal BBM and BLM. In kidney, carnitine uptake was Na -dependent, for both membrane preparations, but in intestine, it was Na -dependent only in BLM. The renal BBM carnitine transporter is likely to be OCTN2 as indicated by a strong reactivity with the anti-OCTN2 polyclonal antibody in Western blot, and by the signi¢cant inhibition of BBM carnitine uptake by the drugs TEA, verapamil, valproate and pyrilamine, in the uptake study. The tissue distribution of OCTN2 showed a broad expression pro¢le of the protein with a strong expression in kidney, heart, skeletal muscle and liver, but with no expression in brain, lungs and small intestine which was in correlation with our functional study. Therefore, OCTN2 not only plays an important role in carnitine reabsorption in kidney, but may also be involved in carnitine distribution and organic cations elimination in several tissues.
